Article Per Year (5 Year)
p-Index From 2019 - 2024
0.888
P-Index
This Author published in this journals
All Journal Jurnal Dunia Farmasi Jurnal Ilmiah Jophus: Journal of Pharmacy UMUS Jurnal Kesehatan Jurnal Abdimas Indonesia
Eko Hidayaturahman Khumaeni
Program Studi D3 ANAFARMA, STIKes Ibnu Sina Ajibarang
Biochemistry, Genetics & Molecular Biology Chemistry Computer Science & IT Economics, Econometrics & Finance Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology Public Health Social Sciences Other

Published : 4 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search
Journal : Jurnal Kesehatan

 1 
ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN ANTIBIOTIK SEFTRIAKSON DAN SEFTAZIDIM PADA PASIEN PNEUMONIA DEWASA DI RAWAT INAP RSUD AJIBARANG PERIODE JANUARI – DESEMBER 2021 Adi Susanto; Eko Hidayaturohman Khumaeni; Lina Septiana
Jurnal Kesehatan Vol. 10 No. 1 (2022): April : Health Journal “Love That Renewed”
Publisher : Sekolah Tinggi Ilmu Kesehatan Santo Borromeus

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55912/jks.v10i1.40

Abstract

Pneumonia is a world health problem with the highest mortality rate, both in developed and developing countries such as Indonesia. Pneumonia is an acute infectious disease that affects the lung parenchyma (alveoli) so that the lung tissue becomes inflamed. To treat pneumonia, appropriate antibiotics are needed, minimal side effects and affordable costs. So it is necessary to study the cost-effectiveness analysis in order to make it easier to choose a more cost-effective treatment in pneumonia patients. The purpose of this study was to determine the cost-effectiveness of the use of antibiotics ceftriaxone and ceftazidime in adult pneumonia patients in Ajibarang Hospital inpatient period January – December 2021. This study was a descriptive study with retrospective data collection. Sampling using total sampling method and data collection using patient medical records. The results showed that the ACER value of the antibiotic ceftriaxone was Rp. 17,468 with an effectiveness of 87%, while the ACER value of ceftazidim is Rp. 15,375 with 100% effectiveness. In the quadrant placement the cost-effectiveness of ceftazidime occupies the dominant column in quadrant II (higher effectiveness with lower cost). Based on the ACER value and cost-effectiveness quadrant, ceftazidime is a more cost-effective therapy than ceftriaxone because it has a lower ACER value and occupies the dominant column.
Co-Authors Adi Susanto Kristian Ubanayo Lina Septiana Muhammad Fajar Fauzi Novita Endang Fitriyani Yulia Maulidatul Karomah